MedTrace Logo

Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents

NCT00375570 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2008-08-18

No results posted yet for this study

Summary

The Purpose of this study is to evaluate the safety of ME-609 for the treatment of recurrent herpes labialis in adolescents.

Conditions

  • Herpes Labialis

Interventions

DRUG

ME-609

Topical treatment 5 times daily for 5 days

Sponsors & Collaborators

  • Medivir

    lead INDUSTRY

Principal Investigators

  • Anders Strand, MD PhD · Department of Medical Sciences, Dermatology and Venereology University Hospital, Uppsala, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-09-30
Completion
2007-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375570 on ClinicalTrials.gov